V. Carr-brendel et al., Immunity to breast cancer in mice immunized with X-irradiated breast cancer cells modified to secrete IL-12, J IMMUNOTH, 22(5), 1999, pp. 415-422
A mouse mammary adenocarcinoma cell line (410.4) originating in a BALB/c mo
use, was transduced with a retroviral vector (TGF-mIL-12-Neo) that encoded
murine IL-12. After confirmation of IL-12-secretion, the cells were tested
for their tumorigenic properties in BALB/c mice. The results indicated that
unlike other tumors modified for cytokine secretion, modification of 410.4
cells to secrete IL-12 (410.4-IL-12 cells) failed to eliminate the cells'
neoplastic growth properties. Progressively growing tumors of 410.4-IL-12 c
ells invariably formed in syngeneic BALB/c mice and led, eventually, to the
animals' death. However, the cells' immunogenic properties were preserved
as indicated by the finding that immunizations with 410.4-IL-12 cells, inac
tivated before injection by X-irradiation, resulted in potent, long-term im
munity toward unmodified 410.4 cells and protected the mice against the mal
ignant proliferation of the breast cancer cells. We conclude that modificat
ion of 410.4 cells for IL-12-secretion augmented the response of syngeneic
BALB/c mice to weakly immunogenic tumor-associated antigens expressed by th
e cells. The increase in the cells' immunogenic properties, however, was in
sufficient to prevent tumor growth in the mice. The results point toward th
e immunotherapeutic potential of X-irradiated tumor cells modified for the
secretion of immune augmenting cytokines.